Cutsem EV, Cuyle PJ, Huijberts S, Yaeger R, Schellens JHM, Elez E, Tabernero J, Fakih M, Montagut C, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Kopetz S , Maharry K, Christy-Bittel J, Gollerkeri A, Grothey A
If you do remember anything, its likely to be a fragment of a dream
Previously, Pfizer designed the drug as a twice-daily pill but it faced discontinuation rates of over 50%, possibly due to side effects
Challenges and Future Directions of GLP-1 'Central Program' Intervention Current challenge: Individual differences and long-term safety Although GLP-1 injections have shown excellent efficacy in clinical trials, their "central plan" interventions still face challenges: Individual metabolic differences There are significant differences in the response of different patients to GLP-1RA, which are related to factors such as gene polymorphism, gut microbiota composition, and metabolic flexibility